参考文献/References:
[1]Earl J, GarciaNieto S, MartinezAvila C, et al. Circulating tumor cells (CTC) and KRAS mutant circulating free DNA (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer,2015,15:1-10.
[2]Gilbey AM, Burnett D, Coleman RE, et al. The detection of circulating breast cancer cells in blood. J Clin Oncol,2004,57(9):903-911.
[3]Court CM, Ankeny JS, Sho S, et al. Circulating tumor cells predict occult metastatic disease and prognosis in pancreatic cancer. Ann Surg Oncol,2018,25(4):1000-1008.
[4]Bidard FC, Huguet F, Louvet C, et al.Circulating tumor cells in locally advanced pancreatic adenocarcinoma: The ancillary study CirCe 07 of the LAP 07 trial. J Clin Oncol,2013,24(8):2057-2061.
[5]Gao P, Jiao SC, Bai L, et al. Detection of circulating tumour cells in gastric and hepatocellular carcinoma: A systematic review. J Int Med Res,2013,41(4):923-933.
[6]Marrinucci D, Bethel K, Kolatkar A, et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol,2012,9(1):1-9.
[7]PaterliniBrechot P, Benali NL. Circulating tumor cells(CTC) detection: Clinical impact and future directions. Cancer Lett,2007,253(2):180-204.
[8]陈颐,王小林.循环肿瘤细胞研究进展及其在胰腺癌诊疗中的应用.复旦学报，2018,45(1):119-136.
[9]Buscail E, Degrandi O, Caumont C, et al. In vitro comparative analysis of Circulating Tumor Cells detection in liquid biopsy for the diagnosis of pancreatic adenocarcinoma.Pancreatology,2017,17(3):S23.
[10]Ma YC, Wang L, Yu FL, et al. Recent advances and prospects in the isolation by size of epithelial tumor cells (ISET) methodology. Technol Cancer Res T,2013,12(4):295-309.
[11]Farace F, Massard C, Vimond N, et al. A direct comparison of cellsearch and ISET for circulating tumourcell detection in patients with metastatic carcinomas. Br J Cancer,2011,105(6):847-853.
[12]Lindsay CR, Le Moulec S, Billiot F, et al. Vimentin and Ki67 expression in circulating tumour cells derived from castrateresistant prostate cancer. BMC Cancer,2016,16:1-11.
[13]Ksiazkiewicz M, Markiewicz A, Zaczek AJ. Epithelial mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells. Pathobiology,2012,79(4):195-208
[14]Budna J, S′wierczewska M, Cies′likowski WA, et al. Comparison of cellsearch, EPISPOT and cellcollector CTC isolation techniques for early diagnostic in highrisk prostate cancer patients. Clin Exp Metastas,2018,35(3):215.
[15]Trifanny Y，Jin TS，Leng LC，et al. Microfluidic enrichment for the single cell analysis of circulating tumor cells. Sci Rep,2016,6:1-12.
[16]Chikaishi Y, Yoneda K, Ohnaga T, et al. EpCAMindependent capture of circulating tumor cells with a universal CTCchip. Oncol Rep,2017,37(1):77-82.
[17]Kraan J, Sleijfer S, Strijbos MH, et al. External quality assurance of circulating tumor cell enumeration using the CellSearch system: A feasibility study. Cytom Part Bclin Cy,2011,80B(2):112-118.
[18]Guglielmi R, Neves RPL, Raba K, et al. Testing a labelfree CTCenrichment method to isolate viable pancreatic cancer CTC. Clin Exp Metastasis,2018,35(3):181.
[19]Lapin M, Tjensvoll K, Oltedal S, et al. Singlecell mRNA profiling reveal transcriptional heterogeneity among pancreatic circulating tumor cells. BMC Cancer,2017,17:1-10.
[20]Court CM, Ankeny JS, Hou S, et al. Single cell mutational analysis of isolated circulating tumor cells in pancreatic cancer. Ann Surg Oncol,2015,22(Suppl 1):S169-S170.
[21]Grafton MMG, Jack RM, Cieslak R, et al. An integrated microfluidic device for circulating tumor cell detection in pancreatic cancer patients. Cancer Res,2013,73(8):1457.
[22]DeAlbuquerque A, Kubisch I, Ernst D, et al. Prognostic significance of multimarker circulating tumor cell analysis in patients with advanced pancreatic cancer. J Clin Oncol,2011,29(15): e14657.
[23]Khoja L, Backen A, Sloane R, et al. A pilot study to explore circulating tumor cells in pancreatic cancer as a novel biomarker.Br J Cancer,2012,106 (3):508-516.
[24]Tavassoli P, Wang L, Park S, et al. Nondestructive microfluidic cellbased assay for determining cell deformability as a function of epithelialtomesenchymal transition. Lab Invest,2013,93(Suppl 1):447A.
[25]Po JW, Roohullah A, Lynch D, et al. Improved ovarian cancer EMTCTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal Ncadherin. J Circ Biomark,2018,7:1-10 .
[26]AlixPanabieres C, Pantel K. Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay. Expert Rev Mol Diagn,2015,15(11):1411-1417.
[27]Li Y, Ma G, Zhao P, et al. Improvement of sensitive and specific detection of circulating tumor cells using negative enrichment and immunostainingFISH. Clin Chim Acta,2018,485:95-102.
[28]Xu Y, Qin T, Li J. Detection of circulating tumor cells using negative enrichment immunofluorescence and an in situ hybridization system in pancreatic cancer.Int J Mol Sci,2017,18(4):1-18.
[29]Ko JA, Bhagwat N, Yee SS, et al. Rapid in situ RNA analysis of circulating tumor cells using magnetic microporebased sorting and Turbo FISH.Cancer Res,2015,75(15):386.
[30]Hinz S, Hendricks A, Wittig A, et al. Detection of circulating tumor cells with CK20 RTPCR is an independent negative prognostic marker in colon cancer patients: a prospective study.BMC Cancer,2017,17:1-11.
[31]Chebouti I, Buderath P, Kuhlmann JD, et al. The presence and persistence of ERCC1 positive circulating tumor cells predicts worse prognosis in primary ovarian cancer patients. Cancer Res,2016,76(14):447.
[32]Xu GL, Shen J, Xu YH, et al. ROR1 is highly expressed in circulating tumor cells and promotes invasion of pancreatic cancer.Mol Med Rep,2018,18(6):5087-5094.
[33]Guglielmi R, Neves RPL, Raba K, et al. Testing a labelfree CTCenrichment method to isolate viable pancreatic cancer CTC. Clin Exp Metastas,2018,35 (3):181.
[34]Barnard RM. Flowcytometry:A flexible tool for biomarker research.Bioanalysis, 2012,20(4):2471-2483.
[35]Nedosekin DA, Sarimollaoglu M, Ye JH, et al. In vivo ultrafast photoacoustic flow cytometry of circulating human melanoma cells using nearinfrared highpulse rate lasers.Cytom Part A,2011,79 A (10):825-833.
[36]Galanzha El, Kim JW, Zharov VP. Nanotechnologybased molecular photoacoustic and photothermal flow cytometry platform for invivo detection and killing of circulating cancer stem cells．Biophotonics,2009,2(12):725-735.
[37]张菊英,张亚衡.免疫磁珠阳性筛选联合流式细胞术对胰腺癌外周血循环肿瘤细胞的诊断价值.中国实验诊断学，2016,4(20):551-554.
[38]Xie ZB, Yao L, Jin C, et al. Circulating tumor cells in pancreatic cancer patients: Efficacy in diagnosis and value in prognosis. Discov Med,2016,22(120):121-128.
[39]Yang G, Zhu Y, Zhang Z ,et al. Clinical significance of pancreatic circulating tumor cells using combined negative enrichment and immunostainingfluorescence in situ hybridization.J Exp Clin Canc Res,2016,35:1-8.
[40]Katherine E, Poruk, Vicente Valero, et al. Circulating tumor cell phenotype predicts recurrence and survival in pancreatic adenocarcinoma. Ann Surg,2016,264(6):1073-1081.
[41]Liu Q, Liao Q, Zhao Y, et al. Myeloidderived suppressor cells (MDSC) facilitate distant metastasis of malignancies by shielding circulating tumor cells (CTC) from immune surveillance. Med Hypothesis,2016,87:34-39.
[42]Effenberger KE, Schroeder C, Hanssen A, et al. Improved risk stratification by circulating tumor cell counts in pancreatic cancer. Clin Cancer Res,2018,24(12):2844-2850.
[43]Anemura M, Furukawa K, Wakasugi M, et al. Live circulating tumor cells as a predictive biomarker of response to neoadjuvant chemoradiotherapy for resectable pancreatic cancer. Cancer Res,2016,76(Suppl 14):S1539.
[44]Pang TCY, Pothula S, Xu Z, et al. Circulating pancreatic stellate (stromal) cells in pancreatic cancea fertile area for novel research. Carcinogenesis,2017,38(6):588-591.
[45]Reza JA, Arnoletti JP, Fanaian N, et al. Portal vein circulating tumor cells (CTC) conform multicellular type clusters in patients with periampullary carcinomas. Ann Surg Oncol,2018,25(Suppl 1):S122.
[46]Liu X, Li C, Li J, et al. Detection of CTCs in portal vein was associated with intrahepatic metastases and prognosis in patients with advanced pancreatic cancer.J Cancer,2018,9(11):2038-2045.
[47]Tao L, Zhang L, Peng Y, et al. Neutrophils assist the metastasis of circulating tumor cells in pancreatic ductal adenocarcinoma: A new hypothesis and a new predictor for distant metastasis. Medicine (Baltimore),2016,95(39):e4932.
[48]Bissolati M, Sandri MT, Burtulo G, et al. Portal veincirculating tumor cells predict liver metastases in patients with resectable pancreatic cancer. Tumor Biol,2015,36(2):991-996.
[49]祝鹏,刘慧颖,姚骏,等.胰腺癌肝转移与循环肿瘤细胞上皮-间质转化表型的关系.肿瘤,2015,8(35):874-882.
[50]Tien YW, Kuo HC, Ho BI, et al. A high circulating tumor cell count in portal vein predicts liver metastasis from periampullary or pancreatic cancer a high portal venous CTC count predicts liver metastases. Medicine,2016,95(16):1-7.
[51]杨静,周颖,金咏梅,等.胰腺癌患者循环肿瘤细胞及TLR4、TLR9、myd88的表达水平与其化疗效果及转移、复发的关系.现代生物医学进展,2017,28(17):5524-5527.
[52]Sato T, Muramatsu T, Tanabe M, et al. Identification and characterization of transforming growth factor betainduced in circulating tumor cell subline from pancreatic cancer cell line. Cancer Sci,2018,109(11):3623-3633.
[53]Kulemann B, Seifert S, Hppner J, et al. Heterogeneous cytological appearance and KRAS mutations in pancreatic circulating tumors cells. Langenbecks Arch Surg,2014,399(3):384.
[54]Dotan E, Alpaugh RK, Ruth K, et al. Prognostic significance of MUC1 in circulating tumor cells in patients with metastatic pancreatic adenocarcinoma. Pancreas,2016,45(8):1131-1135.
[55]Wang X, Sun Q, Liu Q, et al. CTC immune escape mediated by PDL1. Med Hypothesis,2016,93:138-139.
[56]Ahn KS, Hwang JY, Han HS, et al. The impact of acute inflammation on progression and metastasis in pancreatic cancer animal model. Surg Oncol,2018,27 (1):61-69.
[57]Arnoletti JP, Zhu X, Almodovar AJO, et al. Portal venous blood circulation supports immunosuppressive environment and pancreatic cancer circulating tumor cell activation.Pancreas,2017,46(1):116-123.
[58]郑建洲,何流漾,夏蕾,等.循环肿瘤细胞在肿瘤侵袭转移机制中的研究进展及应用前景.国际遗传学杂志,2017,6(40):384-388.
[59]Sergeant G, Roskams T, Van Pelt J, et al. Perioperative cancer cell dissemination detected with a realtime RTPCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma. BMC Cancer,2011,11:1-8.